Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 32 clinical trials
A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis (Beyond ABR)

participants aged ≥13 and <70 years with severe hemophilia A without factor VIII (FVIII) inhibitors or moderate hemophilia A without FVIII inhibitors who are receiving FVIII prophylaxis and who will start

  • 0 views
  • 17 Jun, 2022
  • 3 locations
Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 (270-203)

) based gene therapy vector) in severe Hemophilia A patients with pre-existing antibodies against AAV5.

Factor VIII
hemophilia
  • 0 views
  • 10 Mar, 2022
  • 3 locations
POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

This is a prospective, randomized control trial in which each patient will be randomly assigned to receive either extended half-life factor VIII based replacement therapy or non-FVIII based replacement therapy, which are both standard of care treatment for persons with Hemophilia A.

  • 0 views
  • 04 May, 2022
  • 1 location
Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

Factor VIII (FVIII) is a large plasma glycoprotein that participates in blood coagulation. Loss of circulating FVIII activity due to mutations within the F8 gene results in the X-linked, recessive bleeding disorder hemophilia A. The clinical presentation ranges from a mild to severe bleeding phenotype that correlates with the patient's …

  • 0 views
  • 05 May, 2022
  • 1 location
Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast

Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast

  • 0 views
  • 11 May, 2022
  • 1 location
Gene Therapy for Haemophilia A.

The GO-8 study focuses on assessing safety and efficacy of gene therapy for patients with severe haemophilia A

antihemophilic factor
severe haemophilia a
joint pain
bleeding tendency
arthropathy
  • 301 views
  • 24 Jan, 2021
  • 3 locations
A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A

The goal of this study is to gather more information on safety and efficacy of Kovaltry for the prevention and treatment of bleeds in Chinese children, adolescents/adults with severe hemophilia

  • 0 views
  • 19 Jun, 2022
  • 4 locations
Safety Tolerability and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors

This Phase I/II clinical study will evaluate the safety and efficacy of valoctocogene roxaparvovec in patients with severe haemophilia A and inhibitors to FVIII. Part A of the study will involve

  • 0 views
  • 19 Jul, 2021
  • 2 locations
Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors

-8016. Part one will evaluate the safety, efficacy, and tolerability of SPK-8016 in adult males with clinically severe hemophilia A and no measurable inhibitor against FVIII. Data obtained from Part 1

gene therapy
Factor VIII
immunoglobulins
hemophilia
  • 36 views
  • 23 Mar, 2022
  • 12 locations
Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.

This study is a multi-center, open-label, extension trial to evaluate the safety, efficacy of SCT800 in long term prophylaxis and on-demand treatment in patients with severe hemophilia A who

severe haemophilia a
antihemophilic factor
coagulation factor
  • 0 views
  • 05 Mar, 2022
  • 1 location